Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
TAS-102, Irinotecan, and bevacizumab in pre-treated metastatic colorectal cancer (TABAsCO), a phase II clinical trial.
Boland PM, Mukherjee S, Imanirad I, Vijayvergia N, Cohen SD, Gupta M, Iyer RV, Bakin A, Wang J, Chatley S, Cahill B, Vadehra D, Attwood K, Hochster HS, Fountzilas C. Boland PM, et al. Among authors: hochster hs. Br J Cancer. 2024 Nov;131(8):1290-1297. doi: 10.1038/s41416-024-02845-x. Epub 2024 Sep 7. Br J Cancer. 2024. PMID: 39244627 Clinical Trial.
Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208).
Hochster HS, Catalano P, Weitz M, Mitchell EP, Cohen D, O'Dwyer PJ, Faller BA, Kortmansky JS, O'Hara MH, Kricher SM, Lacy J, Lenz HJ, Verma U, Benson AB. Hochster HS, et al. J Natl Cancer Inst. 2024 Sep 1;116(9):1487-1494. doi: 10.1093/jnci/djae114. J Natl Cancer Inst. 2024. PMID: 38775718 Clinical Trial.
COMPANION-002 A clinical trial of investigational drug CTX-009 plus paclitaxel vs paclitaxel in second line advanced BTC.
Azad N, Hu Z, Sahin I, Iyer R, Aranha O, Hochster H, Pathak P, Paulson AS, Kalyan A, Liao CY, Tran N, Kelley RK, Heestand G, Cosgrove D, El-Khoueiry A, Borad M, Gabrail NY, Majeed U, Du L, Kamath S, Shumway N, Shroff R, Goyal L, Rosales M, Javle M. Azad N, et al. Future Oncol. 2024;20(30):2241-2248. doi: 10.1080/14796694.2024.2351351. Epub 2024 Jun 4. Future Oncol. 2024. PMID: 38861293 Free PMC article.
Response to Hu, Zhou, and Sun.
Hochster HS; E7208 authors. Hochster HS, et al. J Natl Cancer Inst. 2024 Dec 1;116(12):2042. doi: 10.1093/jnci/djae258. J Natl Cancer Inst. 2024. PMID: 39412477 No abstract available.
Randomized trial of TAS-102 for refractory metastatic colorectal cancer.
Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, Sobrero A, Boucher E, Peeters M, Tran B, Lenz HJ, Zaniboni A, Hochster H, Cleary JM, Prenen H, Benedetti F, Mizuguchi H, Makris L, Ito M, Ohtsu A; RECOURSE Study Group. Mayer RJ, et al. N Engl J Med. 2015 May 14;372(20):1909-19. doi: 10.1056/NEJMoa1414325. N Engl J Med. 2015. PMID: 25970050 Free article. Clinical Trial.
A phase II study of FOLFOX combined with nab-paclitaxel in the treatment of metastatic or advanced unresectable gastric, gastroesophageal junction adenocarcinoma: a Big Ten Cancer Research Consortium trial.
Dreyer MS, Mulcahy M, Kocherginsky M, Chen Y, Hochster HS, Kasi PM, Kircher S, Lou E, Ma Y, Uboha NV, Benson AB 3rd. Dreyer MS, et al. Among authors: hochster hs. Oncologist. 2024 Dec 6;29(12):1044-1050. doi: 10.1093/oncolo/oyae236. Oncologist. 2024. PMID: 39293067 Free PMC article. Clinical Trial.
Phase I-II study of OBI-888, a humanized monoclonal IgG1 antibody against the tumor-associated carbohydrate antigen Globo H, in patients with advanced solid tumors.
Tsimberidou AM, Grothey A, Sigal D, Lenz HJ, Hochster HS, Chao Y, Bai LY, Yen CL, Xu D, Saville MW. Tsimberidou AM, et al. Among authors: hochster hs. Cancer Chemother Pharmacol. 2024 Dec;94(6):787-798. doi: 10.1007/s00280-024-04714-z. Epub 2024 Sep 23. Cancer Chemother Pharmacol. 2024. PMID: 39311947 Free PMC article. Clinical Trial.
Trastuzumab Plus Pertuzumab Versus Cetuximab Plus Irinotecan in Patients With RAS/BRAF Wild-Type, HER2-Positive, Metastatic Colorectal Cancer (S1613): A Randomized Phase II Trial.
Raghav KPS, Guthrie KA, Tan B Jr, Denlinger CS, Fakih M, Overman MJ, Dasari NA, Corum LR, Hicks LG, Patel MS, Esparaz BT, Kazmi SM, Alluri N, Colby S, Gholami S, Gold PJ, Chiorean EG, Kopetz S, Hochster HS, Philip PA. Raghav KPS, et al. Among authors: hochster hs. J Clin Oncol. 2025 Jan 6:JCO2401710. doi: 10.1200/JCO-24-01710. Online ahead of print. J Clin Oncol. 2025. PMID: 39761503
141 results